Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

BACKGROUND: Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median progression-free survival of 4.6 months. nab-paclitaxel-based regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Yardley, Denise A., Brufsky, Adam, Coleman, Robert E., Conte, Pierfranco F., Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A., O’Shaughnessy, Joyce, Beck, Robert M., Ko, Amy, Renschler, Markus F., Barton, Debora, Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682258/
https://www.ncbi.nlm.nih.gov/pubmed/26673577
http://dx.doi.org/10.1186/s13063-015-1101-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682258/
https://www.ncbi.nlm.nih.gov/pubmed/26673577
http://dx.doi.org/10.1186/s13063-015-1101-7

Ejemplares similares